The global anti-vascular endothelial growth factor (VEGF) therapeutics market has witnessed substantial development in recent years, largely driven by the rising prevalence of chronic ophthalmic and oncological conditions. Valued at USD 12.09 billion in 2021, the market is expected to grow modestly, registering a compound annual growth rate (CAGR) of 0.4% during the...